Lowest Price Guaranteed From USD 2,499
The global antibody humanization and affinity maturation services market is estimated to grow from $91 million to $127 million by 2030. First discovered in 1975, monoclonal antibodies are considered to be one of the fastest growing therapy segments in the biopharmaceutical industry. In the year 2016, Humira, a monoclonal antibody, generated revenues worth more than USD 16 billion to become the highest selling drug. With a strong development pipeline and high clinical success rate, the market continues to witness increasing adoption of antibody based therapies and products.
The growing industry has faced / continues to face several challenges. One of the biggest hurdles to the growth of antibody based products has been the lack of technical know-how across different stages of drug discovery. This situation is particularly true for the more traditional pharmaceutical companies that have recently ventured into the targeted therapies domain. Some of these companies have mitigated this issue by making specific acquisitions and / or hiring trained personnel to cater to the requirements. However, several others have preferred to out-source these steps to contract services providers. In fact, over the years, a number of services providers offering antibody discovery have been established, and have grown to become an indispensable part of the biopharmaceutical market.
Certain steps of the antibody drug discovery process require advanced expertise, and companies offering these specialized services have attracted significant attention of drug / therapy developers. Two such specific services are to reduce antibody immunogenicity (humanization) and enhance its affinity (affinity maturation). Immunogenicity has continued to be one of the most limiting factors of the clinical success of antibodies. Antibody humanization has emerged as an extensively studied method for reducing antibody immunogenicity. There are several contract services providers that are providing novel technologies beyond the traditional methods to facilitate antibody humanization as well as to enhance antibody affinity. These contract services providers have enabled the drug developers to develop therapeutic antibodies with low immunogenicity and high affinity.
Several recent developments have taken place in the field of antibody humanization and affinity maturation. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
The “Antibody Humanization and Affinity Maturation: Services and Platforms, 2017-2030” report provides a comprehensive view on the current landscape and the future outlook of the antibody humanization and affinity maturation contract research services and platforms market. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In addition to other elements, the report covers the following:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as number of projects being out-sourced, number of projects undertaken per year and expected pricing, we have provided an informed estimate of the likely evolution of the opportunity for antibody humanization and affinity maturation services providers for the period 2017-2030. The base year for the report is 2017. To account for the uncertainties associated with these services and to add robustness to our model, we have provided three forecast scenarios portraying conservative, base and optimistic tracks of the market’s evolution.
The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Aaron Sato (CSO of LakePharma), Andrew C.R. Martin (Reader in Bioinformatics and Computational Biology at University College London) and Thomas Schirrmann (General Manager of YuMab).